PANAMA CITY, Panama — July 9, 2026 — Leads & Copy — Tilray Medical, a division of Tilray Brands, Inc., has officially launched its first medical cannabis product in Panama, a significant step in the company’s global expansion and its mission to increase patient access to pharmaceutical-grade cannabinoid medicines. The introduction of Tilray Oral Solution CBD100 marks a new chapter for the company in Panama and underscores its commitment to serving patients worldwide.
The commercial launch was facilitated by the successful shipment of Tilray Oral Solution CBD100, produced at Tilray Medical’s EU-GMP-certified facilities in Portugal. This product will be distributed through Farmacias Arrocha, a prominent pharmacy network in Panama. Patients will be able to obtain Tilray Oral Solution CBD 100 through medical prescription, providing a regulated and pharmaceutical-quality option for medical cannabis within established healthcare channels.
This development further solidifies Tilray Medical’s status as a geographically diverse medical cannabis company, with a presence in over 20 countries across Europe, Australia, Canada, Latin America, and other growing international markets. The company focuses on advancing access to safe, high-quality cannabinoid-based medicines through regulated healthcare systems.
Rajnish Ohri, President, International, Tilray Brands, emphasized the company’s belief that all patients should have access to safe, consistent, and pharmaceutical-grade medical cannabis. “Our commercial launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines through trusted healthcare systems around the world,” Ohri stated. He added that Tilray Medical is committed to collaborating with healthcare providers, regulators, pharmacists, and patients to shape the future of responsible access, advance medical education, and deliver life-improving treatments.
The launch aligns with Panama’s medical cannabis framework, established under Law 242 of 2021, and recent regulatory advancements by the Ministry of Health. Key among these are Resolution No. 0406 of May 12, 2026, which outlines patient access requirements, and the introduction of the Medical Cannabis Users and Authorized Caregivers Identification System (SIUCMAA) to streamline physician authorization and patient registration.
Tilray Oral Solution CBD100 is manufactured in Portugal under strict European Union Good Manufacturing Practice (EU-GMP) standards. It is intended for use by patients with qualifying medical conditions, as authorized under Panamanian legislation. The product exemplifies Tilray Medical’s dedication to pharmaceutical quality, product consistency, patient safety, and regulatory adherence.
Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a crucial global export hub, supplying EU-GMP-certified medical cannabis products to regulated markets globally. This platform allows the company to efficiently meet increasing international demand while upholding high pharmaceutical manufacturing standards.
The expansion into Panama is part of Tilray Medical’s broader strategy to increase its presence in Latin America, a region experiencing significant growth in the medical cannabis sector. As more governments in the region establish regulatory pathways for cannabinoid-based medicines, Tilray Medical is positioned to support healthcare systems with its trusted products, scientific knowledge, and experience in highly regulated international markets.
As global acceptance of medical cannabis grows, Tilray Medical remains focused on enhancing patient care, supporting clinical education, investing in research, and broadening access to high-quality medical cannabis products to address unmet patient needs.
About Tilray Medical: Tilray Medical is committed to improving patients’ lives by providing safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX, and Broken Coast. The company was one of the first licensed medical cannabis producers in Canada and established the first GMP-certified cannabis production facilities in Europe. Today, Tilray Medical is a leading supplier of medical cannabis in 20 countries across five continents.
About Tilray Brands: Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The company aims to be a leading premium lifestyle brand with a portfolio of brands and innovative products designed to inspire joy and create memorable experiences. Tilray’s platform includes over 40 brands across various sectors, including cannabis, hemp-based foods, and craft beverages.
Source: Tilray Brands, Inc.
